Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lumos Diagnostics HoldingsASX:LDX +15.00% 3-Year EPS without NRI Growth Rate is 26.30% as of Jun. 2026, which is 36% below its 10-year median of 41.25. The stock has 2 warning signs investors should review. Among 662 Medical Devices & Instruments companies, Lumos Diagnostics Holdings ranks better than 73.72% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 26.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 5 years, the highest 3-Year average EPS without NRI Growth Rate of Lumos Diagnostics Holdings was 56.20% per year. The lowest was 26.30% per year. And the median was 41.25% per year.
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Lumos Diagnostics Holdings 3-Year EPS without NRI Growth Rate Related Terms
ASX:LDX vs ABT, SYK, MDT: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, Lumos Diagnostics Holdings's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumos Diagnostics Holdings 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lumos Diagnostics Holdings's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Lumos Diagnostics Holdings's 3-Year EPS without NRI Growth Rate falls into.
Lumos Diagnostics Holdings 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 26.30% mean?
Lumos Diagnostics Holdings (ASX:LDX) has a 3-Year EPS without NRI Growth Rate of 26.30% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Lumos Diagnostics Holdings and its competitors. This is 36% below median its historical median of 41.25. Over the past decade, Lumos Diagnostics Holdings' 3-Year EPS without NRI Growth Rate has ranged from 26.30 to 56.20. According to the industry distribution chart, Lumos Diagnostics Holdings ranks #174 out of 662 companies in the Medical Devices & Instruments industry, placing it in the top 26.3%.
Is Lumos Diagnostics Holdings' 3-Year EPS without NRI Growth Rate too high?
Lumos Diagnostics Holdings' current 3-Year EPS without NRI Growth Rate of 26.30% is 36% below median its 10-year median of 41.25. Over the past 10 years, this metric has ranged from a low of 26.30 to a high of 56.20. The Medical Devices & Instruments industry median 3-Year EPS without NRI Growth Rate is 7.90. Lumos Diagnostics Holdings' value of 26.30% is 232.9% above this industry median. Based on the distribution chart, Lumos Diagnostics Holdings ranks #174 out of 662 companies in the Medical Devices & Instruments industry, which is above the industry midpoint.
How does Lumos Diagnostics Holdings' 3-Year EPS without NRI Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Lumos Diagnostics Holdings ranks #174 out of 662 companies for 3-Year EPS without NRI Growth Rate. This puts Lumos Diagnostics Holdings in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 7.90. Lumos Diagnostics Holdings' value of 26.30% is 232.9% above this benchmark. Historically, Lumos Diagnostics Holdings' own 3-Year EPS without NRI Growth Rate has ranged from 26.30 to 56.20 over the past decade. While the company's 10-year median is 41.25 vs. the industry median of 7.90, Lumos Diagnostics Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 7.90, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lumos Diagnostics Holdings's current 3-Year EPS without NRI Growth Rate of 26.30% is 232.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Lumos Diagnostics Holdings and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumos Diagnostics Holdings's current 3-Year EPS without NRI Growth Rate is 26.30%, which is 36% below median its own 10-year median of 41.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumos Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings (ASX:LDX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.12 — trading 283.3% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 26.30%, which is 36% below median its 10-year median of 41.25 and 232.9% above the Medical Devices & Instruments industry median of 7.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Lumos Diagnostics Holdings (ASX:LDX), the current 3-Year EPS without NRI Growth Rate is 26.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services. The Company operates in two geographical regions, the United States and Australia and the majority of revenue is generated from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LDX has been successfully added to your 
